enrasentan

Enrasentan (sb-217242) is a mixed antagonist of ET(A) and ET(B) receptors that reduces blood pressure, prevents cardiac hypertrophy, and protects myocardial function.

Enrasentan (also known as SB-217242) is a dual receptor endothelin antagonist with a higher affinity for the ET(A) receptor. In animal models of hypertension and cardiac hypertrophy, this compound reduces blood pressure, prevents cardiac hypertrophy, and preserves myocardial function. Enrasentan enhances survival rates, limits left ventricular remodeling, and maintains myocardial performance in hypertensive cardiac hypertrophy and dysfunction.